If you are considering psychedelic-assisted treatment in Italy — for yourself or for someone close to you — the picture in July 2026 is one strong public route, one very small private one, and research that does not yet extend to the classic psychedelics. Esketamine through the hospital system is real and reimbursed; everything involving psilocybin or MDMA is not available outside research, and right now there is no Italian trial to join for either. This guide covers who qualifies, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.
TL;DR Spravato (esketamine) has been reimbursed as a hospital medicine (Classe H) since May 2022 — AIFA Determina 334/2022 — for adults with treatment-resistant depression after at least two failed antidepressants in the current moderate-to-severe episode. Treatment runs through regionally authorized hospital psychiatric centers, with each patient entered in an AIFA monitoring registry. The newer psychiatric-emergency indication was placed in Classe C in 2024 and is not reimbursed. Private ketamine is legal off-label but the market is minimal. Psilocybin and MDMA are strictly controlled, and no Italian trial for either is recruiting as of July 2026 — the recruiting studies are ketamine and esketamine trials in Milan and at four university sites.
At a glance
| Route | Substance | Status in Italy | Who qualifies | Cost |
|---|---|---|---|---|
| Reimbursed esketamine | Esketamine (Spravato) | Classe H since May 2022; running | Adults with treatment-resistant depression: at least two failed antidepressants in the current moderate-to-severe episode, alongside an SSRI or SNRI | Covered by the SSN as a hospital medicine |
| Private ketamine | Ketamine (off-label) | Legal under physician responsibility; very small market | Clinic screening, typically treatment-resistant depression | Self-pay; not reimbursed by the SSN for psychiatric use |
| Psilocybin therapy | Psilocybin | Strictly controlled (DPR 309/1990); research only, no trial recruiting | — | — |
| MDMA therapy | MDMA | Strictly controlled (DPR 309/1990); research only, no trial recruiting | — | — |
| Clinical trials | Ketamine, esketamine | Two recruiting studies | Study-specific criteria | Free |
Full coverage details: Is Spravato reimbursed in Italy?
Esketamine (Spravato): the reimbursed hospital route
Since May 2022, esketamine nasal spray is reimbursed by the national health service as a Classe H medicine — the hospital class — under AIFA Determina n. 334/2022, published in the Gazzetta Ufficiale on 18 May 2022. The reimbursed indication is treatment-resistant major depression: adults whose current moderate-to-severe episode has not responded to at least two different antidepressants taken at adequate dose and duration, treated with esketamine in combination with an SSRI or SNRI.
Classe H shapes everything practical about this route. The medicine is not something you collect at a pharmacy: it is dispensed, administered and monitored inside accredited hospital psychiatric units, and only at centers their region has authorized. After the national decision, Italian regions issued implementing decrees naming which hospitals may prescribe and administer Spravato — Veneto's decree is a published example — so which center you attend depends on where you live. Prescribers also enter every patient into the AIFA monitoring registry, the web-based system Italy uses for closely watched medicines: your eligibility is documented there before treatment starts and your course is tracked in it.
How to start: the route runs through a psychiatrist — in a public mental-health service (CSM) or hospital clinic — who refers you to an authorized center. The practical currency is a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome. The registry entry is built from exactly this record, so assembling it before the first appointment does more than anything else to shorten the process.
Cost: for patients who meet the criteria, the medicine and its administration are covered as hospital care. One distinction matters: esketamine's separate psychiatric-emergency indication — the rapid short-term reduction of depressive symptoms in an acute situation — was classified by AIFA in Classe C in 2024, which means it is not reimbursed by the SSN. In practice, the treatment-resistant depression pathway is the funded one; if a hospital uses esketamine in an emergency context, that use sits outside national reimbursement. Compare how Italy's arrangement fits the rest of the continent in our Europe-wide reimbursement map.
Private ketamine: legal off-label, but a very small market
Racemic ketamine is an authorized medicine in Italy — an anaesthetic — and physicians may use it off-label for depression under their own responsibility, within Italy's off-label rules. What Italy does not have is a meaningful private ketamine-clinic market: unlike Germany or the UK, only a handful of providers advertise this care at all.
The main listed provider is Florence's Istituto di Neuroscienze, the clinical neuroscience center founded by Prof. Stefano Pallanti, which offers ketamine infusions and intranasal esketamine for treatment-resistant depression alongside neuromodulation (TMS and related techniques), pharmacotherapy and psychotherapy. The institute does not publish an itemized fee schedule, so ask for a written cost breakdown — per session and per course — before starting. Off-label psychiatric ketamine is not reimbursed by the SSN, so this route is self-pay from the first appointment.
The standard cautions apply with extra force in a market this small: confirm the treating physician's registration, expect a full psychiatric and medical screening before any treatment decision, and treat any provider who skips that assessment as a warning sign. Our directory for Italy lists what we have verified.
Psilocybin and MDMA: strictly controlled, research only
Psilocybin, MDMA and the other classic psychedelics are controlled under Italy's consolidated narcotics law, DPR 309/1990, in the most restrictive tables — the Ministry of Health has kept the tables current, including a 2022 decree that explicitly added ayahuasca and its component alkaloids. There is no medical-access, compassionate-use or reimbursement route for either substance, and anyone offering psilocybin or MDMA therapy commercially in Italy is operating illegally.
The research picture is equally plain: as of July 2026, no psilocybin or MDMA trial with an Italian site is listed as recruiting on ClinicalTrials.gov. Italy has an increasingly visible professional ecosystem — the Italian Society for Psychedelic Medicine (SIMEPSI) and advocacy groups such as the Luca Coscioni Association argue for research access — but that has not yet translated into recruiting studies or a legislative pathway. If psilocybin- or MDMA-assisted therapy matters to you, the realistic options are watching the registries for new Italian studies or considering trial sites elsewhere in Europe; our trials guide explains how to search and what participation involves.
Clinical trials in Italy
The trials that do exist are ketamine and esketamine studies, and two are recruiting. Blossom currently tracks three trials connected to Italy, two of them active (country report):
- Ketamina (NCT07088380) at IRCCS Ospedale San Raffaele Turro in Milan: a randomized, double-blind Phase 3 study testing whether intravenous ketamine given during electroconvulsive therapy sessions improves outcomes in hospitalized adults with treatment-resistant depression.
- INTENSIFY MDD (NCT05973851): a European Phase 3 study of early-intensified treatment — a second-line antidepressant plus esketamine or ketamine — versus treatment as usual after a first failed antidepressant, with Italian sites in Brescia, Cagliari, Naples and Turin.
Participation is free and legal, but screening is strict and enrolment is never guaranteed. See the trials guide for how phases, placebo and consent work, browse trial sites in Italy, and search ClinicalTrials.gov for current listings.
What to expect in treatment
Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026 — this section and the risks section below.
These routes share a shape — medical screening, supervised administration, structured follow-up — but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common — though they do not occur in everyone — and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.
A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists — and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few — dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
- A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use — any of these may make treatment inappropriate or require specialist assessment.
A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Italy.
Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.
— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess review board
Frequently asked questions
Is Spravato free for patients in Italy?
If you meet the treatment-resistant depression criteria and are treated at a regionally authorized center, the medicine is covered by the SSN as a Classe H hospital medicine — you do not buy it at a pharmacy, and administration happens within hospital care. The gatekeepers are the criteria, the regional list of centers and the AIFA registry, not a payment.
What is the AIFA monitoring registry and does it affect me?
It is the national web-based system AIFA uses to track closely watched medicines. Your prescriber documents your eligibility in it before treatment and records your course in it afterwards. For you it mainly means the documentation of your failed treatments has to be solid — the registry entry is built from it.
Why is the psychiatric-emergency use of esketamine not covered?
AIFA classified that separate indication in Classe C in 2024, which excludes it from SSN reimbursement. The funded pathway is the treatment-resistant depression indication under Determina 334/2022. If cost matters — and it usually does — make sure your case is assessed under the TRD pathway.
Can I get ketamine infusions privately in Italy?
Legally yes: off-label use under physician responsibility is permitted. Practically, the market is very small — Florence's Istituto di Neuroscienze is the main listed provider — and treatment is self-pay, since the SSN does not reimburse psychiatric ketamine. Ask for a written cost plan and a full screening before committing.
Is psilocybin or MDMA therapy available anywhere in Italy?
No. Both are strictly controlled under DPR 309/1990, there is no medical-access route, and as of July 2026 no Italian psilocybin or MDMA trial is recruiting. Anyone selling such therapy in Italy today is acting illegally. The realistic options are registries and trial sites elsewhere in Europe.
Does it matter which region I live in?
Yes, in one specific way: regions authorize the hospital centers that may deliver Spravato, so availability and waiting differ by region. Your psychiatrist will know the authorized center for your area; being treated outside your region is sometimes possible within the SSN, but ask the receiving center first.
Sources
- Gazzetta Ufficiale — AIFA Determina n. 334/2022 (Spravato, Classe H)
- AIFA — monitoring registries for supervised medicines
- Regione Veneto — implementing decree identifying authorized Spravato centers
- Blossom: Italy country report
- Blossom: Medical access in Italy
- Psychedelic Alpha: Worldwide psychedelic laws tracker
- Psychedelic Alpha: Beyond Clinical Trials — psychedelic-assisted therapy in Europe's real world (01/2026)
- EMA: Spravato (esketamine) EPAR
- ClinicalTrials.gov: NCT07088380 — ketamine augmentation of ECT in treatment-resistant depression (Milan)
- ClinicalTrials.gov: NCT05973851 — INTENSIFY MDD (Italian sites: Brescia, Cagliari, Naples, Turin)
- Ministero della Salute — decree of 23 February 2022 updating the DPR 309/1990 tables (G.U. 14 March 2022)
- Istituto di Neuroscienze, Florence — treatments and programs
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations, regional center lists and reimbursement rules change; always verify current requirements with AIFA, your region, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.